Advanced search
Start date

Social pharmaceutical innovation for unmet medical needs - SPIN

Grant number: 19/02519-0
Support Opportunities:Regular Research Grants
Duration: May 01, 2020 - April 30, 2023
Field of knowledge:Health Sciences - Collective Health - Public Health
Convênio/Acordo: Trans-Atlantic Platform for the Social Sciences and Humanities
Principal Investigator:Fernando Mussa Abujamra Aith
Grantee:Fernando Mussa Abujamra Aith
Principal researcher abroad: Conor Douglas
Institution abroad: York University, Canada
Principal researcher abroad: Ellen Moors
Institution abroad: Utrecht University (UU), Netherlands
Principal researcher abroad: Rabeharisoa Vololona
Institution abroad: ParisTech, France
Host Institution: Faculdade de Saúde Pública (FSP). Universidade de São Paulo (USP). São Paulo , SP, Brazil
Associated researchers: Claudio Roberto Cordovil Oliveira ; Jarno Hoekman ; Marina de Neiva Borba ; Robert Peter Hagendijk ; Wouter Boon
Associated scholarship(s):21/05457-5 - Social Pharmaceutical Innovation for Unmet Medical Needs - SPIN Brazil, BP.PD


For many patients around the world, medical drugs and treatments are either unavailable or unaffordable. Many of these patients are from poor economic backgrounds, and are not seen as a viable market by the pharmaceutical industry. Other patients (like those with rare diseases) do not represent a large enough consumer base to justify the pharmaceutical industry's significant research investments required for the development of new treatments. All those patients therefore are facing what is called "unmet medical needs". In the domain of rare diseases, specific policies have been implemented in different countries that have resulted in some growth in the number of drugs for these diseases. However, many conditions are still lacking treatments, and when they are available, they are typically very expensive and thus inaccessible and unsustainable. In recent years, forms of social pharmaceutical innovation (SPIN) have emerged, which are novel models of research and development (R&D) that seek to address health inequalities and vulnerabilities related to rare diseases and other unmet medical needs. SPIN is not driven exclusively by profit making, and is characterized by collaborations between private companies, public institutions and diverse concerned groups (including patient organizations). Our project brings together teams from Canada, Brazil, France and the Netherlands with longstanding expertise in social aspects relating to pharmaceutical innovation. We will be conducting cross-national comparative research on different kinds of SPIN, namely R&D partnerships, alternative forms of provision and licensing, and alternative regulatory frameworks for coverage. Our objective is to provide a detailed understanding of the medical, social, economic, political, and regulatory contexts that shape these SPIN initiatives. In doing so, we will be disseminating the experiences of those directly involved in the SPIN initiatives we are studying, and will thus be contributing to SPIN itself. (AU)

Articles published in Agência FAPESP Newsletter about the research grant:
Articles published in other media outlets (0 total):
More itemsLess items

Scientific publications
(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)
DOUGLAS, CONOR M. W.; AITH, FERNANDO; BOON, WOUTER; DE NEIVA BORBA, MARINA; DOGANOVA, LILIANA; GRUNEBAUM, SHIR; HAGENDIJK, ROB; LYND, LARRY; MALLARD, ALEXANDRE; MOHAMED, FAISAL ALI; et al. Social pharmaceutical innovation and alternative forms of research, development and deployment for drugs for rare diseases. ORPHANET JOURNAL OF RARE DISEASES, v. 17, n. 1, p. 13-pg., . (19/02519-0)

Please report errors in scientific publications list using this form.